|Page (1) of 1 - 08/29/12||email article||print page|
Eli Lilly (LLY) had its price target increased by Bank of America/Merrill Lynch due to Ramucirumab's potential as a successful cancer drug. A $52 price target was issued with a buy rating.
|Analyst Moves: LLY, LXK|
Source:GrabNetworks (c). All Rights Reserved